Phase 2 N=21 CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Previously Untreated Peripheral T-cell Lymphoma
Primary: Complete Response Rate — 75 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03 — 4; 14; 29; 1 Participants
Phase 2 N=391 Efficacy and Safety Study of SUNPG1623
Active Psoriatic Arthritis
Primary: Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate — 0.7949; 0.7722; 0.7143; 0.7308 proportion of subjects — p=0.0001
Phase 2 N=20 Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants
Phase 2 N=70 Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Primary: Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at 24 Hrs — -15.51; -12.98; -12.94; -7.27 Scores on a Scale — p=0.0013
Phase 2 N=61 Idebenone for Primary Progressive Multiple Sclerosis
Multiple Sclerosis · Primary Progressive Multiple Sclerosis
Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year
Phase 2 N=87 A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Neoplasms
Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) — 1; 1; 1; 5 Participants
Phase 2 N=90 NAC for Treating Comorbid PTSD and SUD
Posttraumatic Stress Disorder (PTSD) · Alcohol Use Disorder (AUD) · Substance Use Disorder (SUD)
Primary: Change in Alcohol Use Disorder Severity — -2.65; -2.82 drinking days reduction
Phase 2 N=111 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Haemoglobin A1c (HbA1c) — 0.2; -1.7; -2.0; -1.8 Percentage of HbA1C — p=<0.001
Phase 2 N=36 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Breast Cancer · Brain Tumor - Metastatic
Primary: CNS Objective Response Rate (ORR) — 5; 14; 0 percentage of participants
Phase 2 N=265 AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
Lupus Nephritis
Primary: Number of Subjects Achieving Complete Renal Remission at 24 Weeks — 29; 24; 17; 60 Participants — p=0.045
Phase 2 N=700 A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change From Baseline Osteoarthritis (OA) Pain in the Target Knee as Assessed by the Weekly Average of Daily Pain Numeric Rating Scale (NRS) — -2.77; -2.93; -2.43; -3.03…
Phase 2 N=19 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
Prostate Cancer
Primary: Localizing Tumors — 128; 64 Areas of the body
Phase 2 N=20 Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Primary: Ratio to Baseline in Peripheral Blood Eosinophil Counts After 6 Months of Treatment — 0.06 ratio to baseline — p=< 0.001
Phase 2 N=45 Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration.
Short Duration Lower Limb Surgery Via Spinal Anaesthesia
Primary: Time to Regression of Spinal Block — 40.8; 39.4; 41.5 minutes